Multicenter observational study evaluating minimal residual disease in adult acute myeloid leukemia treatment -FBMTG AML-MRD-

Multicenter observational study evaluating minimal residual disease in adult acute myeloid leukemia treatment -FBMTG AML-MRD- - FBMTG AML-MRD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059800

Enrollment

300

Registered

2025-11-17

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) AML patients aged 18 to 85 years at the time of consent 2) Patients undergoing initial treatment who have not received chemotherapy or radiation therapy 3) AML patients morphologically diagnosed as AML M0, 1, 2, 4, 5, 6, or 7 4) Patients who have provided written informed consent for this study after receiving an explanation.

Exclusion criteria

Exclusion criteria: Cases that the attending physician judged to be inappropriate

Design outcomes

Primary

Measure	Time frame
Relationship between the presence or absence of MRD and survival rate/recurrence rate	—

Countries

Japan

Contacts

Public ContactTakuji Yamauchi

Kyushu University Hospital Department of Hematology, Oncology and Cardiovascular Medicine

yamauchi.takuji.355@m.kyushu-u.ac.jp092-642-5230

Outcome results